Lupus (SLE): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 80
• BCMA 38
• STING 0
• CD20 9
• SGLT2 3
• STAT3 0
• NLRP3 0
• mTOR 0
• JAK 0
• TNF 0
• IL-17 1
• IL-6 0
• PI3K 0
• CD40 0
• TYK2 0
• CTLA-4 0
• FOXP3 0
• PD-1 0
• PPAR 0
• AMPK 0
• CD38 1
• IL-1 0
• NRF2 0
• TP53 0
• AKT 0
• AQP4 0
• CD22 1
• CXCR4 0
• IL-23 0
• APOL1 0
• BRD4 0
• BTK 0
• CTNNB1 0
• GPX4 0
• HIF-1 0
• HMGB1 0
• IL-15 1
• MAPK 0
• PD-L1 0
• SIRT1 0
• TIGIT 0
• TLR4 0
• ACE2 0
• ANGPTL3 0
• BCL-2 0
• CD123 0
• COX-2 0
• DPP-4 0
• ERK 0
• EZH2 0
• FGFR 0
• FTO 0
• G6PD 0
• GLP-1 0
• IDO1 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MDM2 0
• METTL3 0

24 of 1,792 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Identification and functional characterization of ultra-rare variants in childhood lupus

  University of Oklahoma Hlth Sciences Ctr· Oklahoma City, United States· US$38,889 awarded in fiscal year 2026· until Oct 2029

• NIH NIAID · F30

  Regulation of type I interferon signaling by A20 (TNFAIP3) in autoimmune and autoinflammatory disease

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$55,114 awarded in fiscal year 2026· until Oct 2029

• NIH NIAID · F31

  Genetic and cellular mechanisms underlying resistance to gammaherpesvirus infection

  University of Vermont & St Agric College· Burlington, United States· US$34,654 awarded in fiscal year 2026· until Sept 2028

• NIH NIDCR · R01

  Restoring responses to immunotherapy in metastatic lymph nodes in HNSCC

  University of California, San Francisco· San Francisco, United States· US$684,832 awarded in fiscal year 2026· until Jul 2031

• NIH NIA · R41

  Brain-targeted antibody for Alzheimer's disease therapy

  Nanopx Biosciences, Llc· Chapin, United States· US$483,457 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Metabolic microenvironments in humoral immunity (MicroMeta)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €1,990,728· until Jan 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Early and sensitive detection of renal involvement and treatment responses in lupus patients using non-invasive biomarkers (EARLINESS)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spain· EU contribution €226,441· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Understanding the Interaction of T cells and Immune Complexes in Systemic Lupus Erythematosus (TICI-SLE)

  Charite - Universitaetsmedizin Berlin· Berlin, Germany· EU contribution €265,648· until Aug 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SInGle cells iN AuToimmUne inflammatoRy disEases (SIGNATURE)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spain· EU contribution €2,630,239· until Dec 2026· 7 countries

9 of 887 running projects, newest first. Listed amounts together: US$550.9m + €5.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  NCT05268289· Novartis Pharmaceuticals· Updated 12 Nov 2026

  “The decision to conclude the study after Part 1 LPLV is based on strategic considerations by the Sponsor.”Registry text, quoted unchanged. Source

• Withdrawn

  Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

  NCT05504187· Kira Pharmacenticals (US), LLC.· Updated 9 Nov 2026

  “Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns”Registry text, quoted unchanged. Source

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Terminated

  A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

  NCT06943937· China Immunotech (Beijing) Biotechnology Co., Ltd.· Updated 14 Oct 2026

  “Sponsor decision to discontinue; the study is no longer being pursued due to sponsor strategic reprioritization and resource allocation. The decision was not based on safety concerns. Enrolled participants will complete safety follow-up per protocol.”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

  NCT07583030· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Updated 2 Oct 2026

  “pipeline strategy change”Registry text, quoted unchanged. Source

• Terminated

  NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

  NCT07083349· Base Therapeutics (Shanghai) Co., Ltd.· Updated 30 Sept 2026

  “poor accrual”Registry text, quoted unchanged. Source

• Terminated

  KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

  NCT06342960· Kyverna Therapeutics· Updated 31 Aug 2026

  “Study discontinued due to sponsor decision.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

  NCT06984341· Genentech, Inc.· Updated 5 Aug 2026

  “Decision of Sponsor.”Registry text, quoted unchanged. Source

• Withdrawn

  C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

  NCT06935474· AbelZeta Inc.· Updated 16 Jul 2026

  “Sponsor decision to discontinue development and pursue an alternative clinical development strategy”Registry text, quoted unchanged. Source

• Terminated

  COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

  NCT05000216· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 10 Jun 2026

  “The study was closed due to continued enrollment hurdles.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

  NCT04976322· UCB Biopharma SRL· Source

• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  NCT07430306· AstraZeneca· Source

• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

  NCT06576271· GlaxoSmithKline· Source

• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  NCT05268289· Novartis Pharmaceuticals· Source

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Source

• A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Boehringer Ingelheim· Source

• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

  NCT04963296· Hoffmann-La Roche· Source

• A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]

  NCT07840287· EMD Serono Research & Development Institute, Inc.· Source

• Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· AstraZeneca· Source

• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Novartis Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 33
• Mendelian Randomization Analysis 42
• CRISPR-Cas Systems 1
• Gene Expression Profiling 102
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 35
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 35
• Immunohistochemistry 8
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 49
• Machine Learning 38
• Deep Learning 3
• Cohort Studies 112
• Genome-Wide Association Study 55

• An Exploratory Clinicopathological Study Investigating Immunohistochemical Markers (CD61 and Fibrin) for Detecting Platelet Aggregates and Fibrin Deposition in Lupus Nephritis.

  Int J Rheum Dis, Sept 2026

• Kidney-infiltrating proteinase 3-positive granulocytes are abundant in lupus nephritis.

  Rheumatology (Oxford), Sept 2026

• Interstitial palladin is associated with tubulointerstitial chronicity and adverse outcomes in patients with lupus nephritis.

  Lupus, Aug 2026

• A case of lupus nephritis combined with fibrillary glomerulonephritis diagnosed using mass spectrometry and immunohistochemistry of DNAJB9.

  Clin Nephrol, Jul 2026

• Differential glomerular expression patterns of Th17-related cytokines in Mexican patients with lupus nephritis.

  Lupus, Nov 2025

• Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.

  J Immunol, Feb 2017

• Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis.

  Curr Med Chem, Jan 2012

• Treatment of indeterminate cell histiocytosis with pravastatin.

  J Am Acad Dermatol, May 2011

See which targets of this disease your abstract mentions, and go to the people working on them.